The European Commission on Friday extended the authorization of the Imvanex mpox vaccine to teenagers aged 12 to 17.

By Shubham Batra (Reuters) -European shares slipped on Friday after a rally in the previous session spurred by the U.S.

Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...

The European Medicines Agency also said that extra doses of the Moderna and Pfizer-BioNTech vaccines could be given to people with underlying health conditions as early as 28 days after a second dose.

HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

Bank of America Securities analyst Tazeen Ahmad has maintained their bullish stance on APLS stock, giving a Buy rating yesterday. Tazeen Ahmad ...

EMA’s human medicines committee elects Bruno Sepodes as new chair: Amsterdam, The Netherlands Friday, September 20, 2024, ...

Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal ...

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Bavarian Nordic recently filed an application with the European Medicines Agency to extend the approval to children aged 12 to 17, the company said in a statement. Another mpox vaccine ...